WO2007048022A3 - Antibody-polypeptide fusion proteins and methods for producing and using same - Google Patents

Antibody-polypeptide fusion proteins and methods for producing and using same Download PDF

Info

Publication number
WO2007048022A3
WO2007048022A3 PCT/US2006/041215 US2006041215W WO2007048022A3 WO 2007048022 A3 WO2007048022 A3 WO 2007048022A3 US 2006041215 W US2006041215 W US 2006041215W WO 2007048022 A3 WO2007048022 A3 WO 2007048022A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
methods
constant domain
producing
same
Prior art date
Application number
PCT/US2006/041215
Other languages
French (fr)
Other versions
WO2007048022A2 (en
Inventor
Anke Kretz-Rommel
Naveen Dakappagari
Martha Wild
Cecilia Orencia
Katherine S Bowdish
David R Gies
Jeremy P Springhorn
Original Assignee
Alexion Pharma Inc
Anke Kretz-Rommel
Naveen Dakappagari
Martha Wild
Cecilia Orencia
Katherine S Bowdish
David R Gies
Jeremy P Springhorn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Anke Kretz-Rommel, Naveen Dakappagari, Martha Wild, Cecilia Orencia, Katherine S Bowdish, David R Gies, Jeremy P Springhorn filed Critical Alexion Pharma Inc
Publication of WO2007048022A2 publication Critical patent/WO2007048022A2/en
Publication of WO2007048022A3 publication Critical patent/WO2007048022A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are antibody fusions wherein a peptide has been incorporated into the constant domain of an antibody. The peptides may be incorporated at hydrophobic regions within the constant domain and/or between proteasomal cleavage sites that are either naturally occurring or introduced. Also provided are antibody fusions wherein a peptide has been attached to the C-terminus of the constant domain of an antibody heavy or light chain through a cleavable linker. Methods for using the antibody fusions include therapeutic applications, such as immune modulation and selective cell killing, and research applications, such as screening assays to identify internalizing antibodies or cytotoxic agents.
PCT/US2006/041215 2005-10-21 2006-10-20 Antibody-polypeptide fusion proteins and methods for producing and using same WO2007048022A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72940405P 2005-10-21 2005-10-21
US60/729,404 2005-10-21

Publications (2)

Publication Number Publication Date
WO2007048022A2 WO2007048022A2 (en) 2007-04-26
WO2007048022A3 true WO2007048022A3 (en) 2007-09-13

Family

ID=37891461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/041215 WO2007048022A2 (en) 2005-10-21 2006-10-20 Antibody-polypeptide fusion proteins and methods for producing and using same

Country Status (1)

Country Link
WO (1) WO2007048022A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP7064670B2 (en) 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． Peptide construct with a linker that can be cleaved by a protease

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101538328B (en) * 2007-06-15 2011-07-27 中国疾病预防控制中心病毒病预防控制所 Humanized neutralizing engineered antibody for targeting avian influenza virus H5N1
CN101092456B (en) * 2007-06-15 2010-11-10 中国疾病预防控制中心病毒病预防控制所 Gene engineering antibody of human source neutrality for anti virus H5N1 of bird flu
EP2168590A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
EP2401302A4 (en) 2009-02-24 2013-10-09 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides
EP3626739A1 (en) * 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
CA2906096C (en) * 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN105017428B (en) * 2014-05-13 2018-09-11 中国人民解放军军事科学院军事医学研究院 Double targent fused proteins and its encoding gene and application
US20170210818A1 (en) * 2014-06-06 2017-07-27 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
DK3277719T3 (en) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc POLYPEPTIDER
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
JP7092881B2 (en) 2017-11-01 2022-06-28 エフ．ホフマン－ラ ロシュ アーゲー TriFab Contour Body
WO2019133827A1 (en) * 2017-12-29 2019-07-04 Board Of Regents, The University Of Texas System Antimicrobial nanobodies
WO2019238686A1 (en) * 2018-06-13 2019-12-19 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. Peptides having inhibitory activity on muscarinic receptor m3
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114478783B (en) * 2022-01-07 2022-11-29 陕西脉元生物科技有限公司 ENO2 monoclonal antibody, and preparation method and application thereof
WO2023240215A1 (en) * 2022-06-09 2023-12-14 The Children's Medical Center Corporation Methods and compositions for enhanced antigen presentation in the tumor microenvironment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031483A1 (en) * 1994-05-13 1995-11-23 Eclagen Limited Improvements in or relating to peptide delivery
WO1996022377A1 (en) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation of t-cells by modified, antigenic immunoglobulins
WO2002088317A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031483A1 (en) * 1994-05-13 1995-11-23 Eclagen Limited Improvements in or relating to peptide delivery
WO1996022377A1 (en) * 1995-01-19 1996-07-25 Armitage, Ian, M. Activation of t-cells by modified, antigenic immunoglobulins
WO2002088317A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU C ET AL: "FcgammaRI-targeted fusion proteins result in efficient presentation by human monocytes and antagonist T cell epitopes", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 9, 1 November 1996 (1996-11-01), pages 2001 - 2007, XP002131533, ISSN: 0021-9738 *
LUNDE E ET AL: "Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antige npresentation by B cells", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 17, 1999, pages 670 - 675, XP002227236, ISSN: 1087-0156 *
LUNDE E ET AL: "Troybodies and pepbodies", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 30, no. PART 4, 2002, pages 500 - 506, XP002227237, ISSN: 0300-5127 *
TUNHEIM GRO ET AL: "Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 77, no. 3, March 2005 (2005-03-01), pages 303 - 310, XP002432577, ISSN: 0741-5400 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193794B2 (en) 2006-06-07 2015-11-24 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
US9334329B2 (en) 2007-12-18 2016-05-10 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
JP7064670B2 (en) 2015-03-31 2022-05-11 ソリッソ ファーマシューティカルズ，インク． Peptide construct with a linker that can be cleaved by a protease

Also Published As

Publication number Publication date
WO2007048022A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007048022A3 (en) Antibody-polypeptide fusion proteins and methods for producing and using same
WO2007048037A3 (en) METHODS FOR GENERATING MONOVALENT IgG
CY1118504T1 (en) THREE-TERM FUEL PROTECTION PROCESS OF CONNECTOR NO40 IN THE AESOFEURIN AREA AND METHODS OF USE
EP2535351A3 (en) Dual specificity antibody fusions
MY148646A (en) Anti-psgl-1 antibodies
EP2301570B8 (en) Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated and conjugated antibodies, antibody combinations and fusion protein
EP1553975B8 (en) Optimized fc variants and methods for their generation
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
NZ600022A (en) Anti CD37 antibodies
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
SI1883698T2 (en) Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2006002161A3 (en) Modulators of odorant receptors
WO2004049794A3 (en) Single chain antibodies produced in a transgenic mouse
WO2004041865A3 (en) Stabilized single domain antibodies
WO2007044616A3 (en) Optimized anti-cd30 antibodies
EP2363416A3 (en) Anti-platelet membrane glycoprotein VI monoclonal antibody
EP3970746A3 (en) Polypeptide variants and uses thereof
WO2002099119A3 (en) B7-related nucleic acids and polypeptides useful for immunomodulation
CY1110157T1 (en) CHEMICAL RECOVERY ANTIGENS OF TOXOPLASMA GONDII
WO2007115230A3 (en) A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
NZ591492A (en) Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
WO2011064257A3 (en) Monospecific polypeptide reagents
WO2008035217A3 (en) Fusion proteins comprising two or more igg binding domains of streptococcal protein g.
WO2014144911A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06817264

Country of ref document: EP

Kind code of ref document: A2